Hydroxychloroquine does not reduce mortality, RECOVERY trial finds

Hydroxychloroquine does not reduce mortality, RECOVERY trial finds

Recovery trial

The RECOVERY trial, a large randomised controlled trial in the U.K. to test five drugs, including hydroxychloroquine, has found no clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19.
The trial investigators found that there was no significant benefit in mortality reduction in the intervention group, which was the primary objective.
The RECOVERY trial began in March.
It is a dynamic trial assessing five candidate drugs and convalescent plasma therapy for treating COVID-19 in patients in U.K. hospitals. The trial has enrolled over 11,000 patients.
On June 4, following the retraction of The Lancet paper on use of hydroxychloroquine, the U.K. Medicines and Healthcare Products Regulatory Agency wanted the independent Data Monitoring Committee of the RECOVERY trial to carry out an additional review.
It also asked the investigators to look at the unblinded data in the hydroxychloroquine arm.

No beneficial effects

It then came to light that the drug did not have the desired beneficial effects
According to the release, a total of 1,542 patients were randomised to receive hydroxychloroquine for 10 days while 3,132 patients in the control arm received only standard care.
The researchers found that there was “no significant difference in the primary endpoint of 28-day mortality”.
While mortality was 25.7% in the intervention group (who were administered HCQ), the control group had 23.5% mortality, which is not statistically significant.

Outcomes measured

The primary outcome tested was reduction in all-cause mortality within 28 days of randomisation.
The secondary outcomes measured were to assess any reduction in duration of hospital stay and need for and duration of ventilator or ECMO within 28 days and up to six months after randomisation.

Huge speculation

Deputy Chief Investigator Martin Landray from the University of Oxford says: “There has been huge speculation and uncertainty about the role of hydroxychloroquine as a treatment for COVID-19, but an absence of reliable information from large randomised trials.
The preliminary results from the RECOVERY trial are quite clear — hydroxychloroquine does not reduce the risk of death among hospitalised patients with this new disease.”

Post-exposure prophylaxis

Another trial found that hydroxychloroquine drug was not effective even as a post-exposure prophylaxis in asymptomatic participants who have had high-risk exposure with a confirmed COVID-19 case.
Nearly 88% (719 of 821 participants) had such high-risk exposure.
The results of the trial published in The New England Journal of Medicine found that the incidence of COVID-19 illness was not statistically significant in the group that received the drug compared with the control group.
While 49 of 414 (11.8%) participants who received the drug developed illness, 58 of 407 (14.3%) participants who got the placebo fell ill.
Side-effects were more in the intervention group but no serious adverse events were reported.

Source: TH

Join Our Telegram

COVID-19 taking an emotional toll on children

Persistent global transmission of chikungunya from India

E-pharmacies

08 Mar, 23
SHARE

E-pharmacies The Ministry of Health sent "show cause" letters to at least 20 businesses in February 2023 for online drug sales, including Tata-1mg, Flipkart, Apollo, PharmEasy, Amazon, and Reliance Netmeds. What is e-pharmacy? E-pharmacy refers to the purchasing and selling of drugs and other pharmaceutical products through a

Punchhi Commission Report

08 Mar, 23
SHARE

Punchhi Commission Report The Punchhi Commission's report on relations between the federal government and its constituent states will now be reviewed for state responses, according to the Union Ministry of Home Affairs (MHA). Historical Background: A Commission on Centre-State Relations was established by the Indian government,

Indo-German Relations

08 Mar, 23
SHARE

Indo-German Relations Olaf Scholz, the Chancellor of Germany, recently paid a bilateral visit to India. It is Scholz's first trip to India after taking office as German Chancellor in December 2021, ending Angela Merkel's illustrious 16-year reign. About the news: The visit of the German chancellor is significant because i

India Denmark Cooperation

07 Mar, 23
SHARE

India Denmark Cooperation During the "India-Denmark: Partners for Green and Sustainable Development Conference" in New Delhi, the Union Minister for Environment, Forests, and Climate Change said that India and Denmark can work together to show that reaching ambitious climate and sustainable energy targets is possible. Since the Gr

Mob lynching and Cow Vigilantism

07 Mar, 23
SHARE

Mob lynching and Cow Vigilantism The recent lynching and burning of two men in Haryana on the basis of allegations of unlawful cow slaughter, smuggling, or transportation bring attention to the problem of mob lynching. About cow vigilantism: Mob attacks carried out in the guise of "cow protection" primarily target Mus